Green Cross Corp
KRX:006280

Watchlist Manager
Green Cross Corp Logo
Green Cross Corp
KRX:006280
Watchlist
Price: 170 200 KRW 2.1% Market Closed
Market Cap: 1.9T KRW
Have any thoughts about
Green Cross Corp?
Write Note

Green Cross Corp
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Green Cross Corp
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Green Cross Corp
KRX:006280
Current Portion of Long-Term Debt
â‚©31B
CAGR 3-Years
-38%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Current Portion of Long-Term Debt
â‚©175.7B
CAGR 3-Years
40%
CAGR 5-Years
27%
CAGR 10-Years
-1%
SK Bioscience Co Ltd
KRX:302440
Current Portion of Long-Term Debt
â‚©8.1B
CAGR 3-Years
-14%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Current Portion of Long-Term Debt
â‚©2.7B
CAGR 3-Years
20%
CAGR 5-Years
18%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Current Portion of Long-Term Debt
â‚©23.6B
CAGR 3-Years
71%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Current Portion of Long-Term Debt
â‚©88.9B
CAGR 3-Years
11%
CAGR 5-Years
297%
CAGR 10-Years
N/A
No Stocks Found

Green Cross Corp
Glance View

Market Cap
1.9T KRW
Industry
Biotechnology

Green Cross Corporation, rooted in South Korea, has built a formidable presence in the biopharmaceutical industry, primarily focusing on the development and commercialization of vaccines, plasma-derived products, and therapeutic proteins. Founded in 1967, the company initially garnered attention for its innovative efforts in producing hepatitis B vaccines. Over the years, Green Cross expanded its repertoire to include a wide array of biologics. Its operations are vertically integrated, encompassing everything from initial research and development to production and marketing. The company leverages its advanced manufacturing facilities and cutting-edge technology to maintain stringent quality standards and competitive pricing—a strategy that has allowed it to grow both domestically and internationally. A crucial revenue stream for Green Cross arises from its plasma derivatives segment, where the collection and processing of human plasma form the backbone of multiple high-demand medical products, including immunoglobulins, albumin, and clotting factors. Green Cross also benefits from partnerships and collaborations that extend its global footprint, fostering innovation through shared resources and knowledge. Export-driven sales further bolster revenue, as the company taps into growing healthcare needs across various markets around the globe. In essence, Green Cross capitalizes on a meticulous blend of research innovation, quality control, and strategic market expansion, solidifying its role as a key player in the global biopharmaceutical landscape.

Intrinsic Value
216 615.19 KRW
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Green Cross Corp's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
31B KRW

Based on the financial report for Sep 30, 2024, Green Cross Corp's Current Portion of Long-Term Debt amounts to 31B KRW.

What is Green Cross Corp's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
-21%

Over the last year, the Current Portion of Long-Term Debt growth was -85%. The average annual Current Portion of Long-Term Debt growth rates for Green Cross Corp have been -38% over the past three years , -21% over the past five years .

Back to Top